TSX gains on big banks strength
CAMBRIDGE, MA—Rajavelu Esther, the Chief Financial Officer and Chief Business Officer of Spero Therapeutics , Inc. (NASDAQ:SPRO), recently executed a stock transaction involving the sale of 20,689 shares of the company’s common stock. The shares were sold at a price of $0.78 each, totaling $16,137.
The sale, dated February 5, 2025, was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on February 1, 2024. Following this transaction, Esther holds 724,720 shares in the company. According to InvestingPro analysis, the stock appears undervalued despite falling 30.9% over the past six months. Subscribers can access 8 additional ProTips and comprehensive financial metrics in the Pro Research Report.
Additionally, Esther acquired 366,139 shares through the vesting of RSUs at no cost, with the shares set to vest in increments over the coming years, contingent upon continued service. The company’s stock currently trades at $0.88, with analysts setting a $5.00 price target.
In other recent news, Spero Therapeutics has announced interim leadership changes amid a Securities and Exchange Commission inquiry into public disclosures made earlier this year. Esther Rajavelu has been appointed as Interim President and CEO, while Frank Thomas has taken on the role of Chairman of the Board. Despite this, the company’s Phase 3 PIVOT-PO trial for Tebipenem HBr, an oral antibiotic for complicated urinary tract infections, has surpassed 60% enrollment and is expected to be fully enrolled by the second half of 2025.
H.C. Wainwright has reiterated its Buy rating on Spero Therapeutics, highlighting the company’s progress in its Phase 3 trial for Tebipenem HBr. The firm expressed confidence in the timeline of the PIVOT-PO program, anticipating that top-line results could become available in early 2026. On the other hand, TD Cowen has downgraded its rating from Buy to Hold due to uncertainties regarding the timing of upcoming catalysts for the company.
Spero Therapeutics continues to work on its pipeline projects, despite a recent setback with its Phase 2a trial of SPR720 for Non-Tuberculous Mycobacterial-Pulmonary Disease not meeting its primary endpoint. The company is also planning a Phase 2 trial for SPR206, aimed at treating bacterial pneumonia, pending non-dilutive funding. The company maintains a cash balance sufficient to fund operations into mid-2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.